Real-world treatments and outcomes of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a Japanese claims analysis
Takero Shindo, Mami Shindo · 2026
Read Real-world treatments and outcomes of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a Japanese claims analysis by Takero Shindo, Mami Shindo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13638707.txt.
Description
Takero Shindo and Mami Shindo analyzed real-world treatment of chronic graft-versus-host disease after donor stem cell transplant in Japan, a 2026 claims study of a burdensome complication. Chronic graft-versus-host disease inflames and scars multiple organs, yet practical data on drug sequences and outcomes remain thin. The authors mined anonymized insurance claims for 1,090 patients, tracking systemic therapy, complications, and survival patterns by age and donor cell source.
Eighty-one percent received systemic immune suppression, most often tacrolimus plus steroids at first. Second-line therapy reached 44 percent and third-line 23 percent, with steroid-only treatment most common at third line. Treatment was paused in 79 percent and restarted in about half, while younger recipients and cord blood recipients restarted less often and died less often. Most complications eased over time, except chronic bone, eye, and breathing disorders.
Catalog record
| CREATOR | Takero Shindo, Mami Shindo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |